JPWO2021256524A1 - - Google Patents

Info

Publication number
JPWO2021256524A1
JPWO2021256524A1 JP2022531894A JP2022531894A JPWO2021256524A1 JP WO2021256524 A1 JPWO2021256524 A1 JP WO2021256524A1 JP 2022531894 A JP2022531894 A JP 2022531894A JP 2022531894 A JP2022531894 A JP 2022531894A JP WO2021256524 A1 JPWO2021256524 A1 JP WO2021256524A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022531894A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021256524A1 publication Critical patent/JPWO2021256524A1/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
JP2022531894A 2020-06-18 2021-06-17 Pending JPWO2021256524A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020105104 2020-06-18
PCT/JP2021/022968 WO2021256524A1 (ja) 2020-06-18 2021-06-17 免疫原性低減型低分子抗体とその製造法

Publications (1)

Publication Number Publication Date
JPWO2021256524A1 true JPWO2021256524A1 (https=) 2021-12-23

Family

ID=79268044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022531894A Pending JPWO2021256524A1 (https=) 2020-06-18 2021-06-17

Country Status (5)

Country Link
US (1) US20230227536A1 (https=)
EP (1) EP4169940A1 (https=)
JP (1) JPWO2021256524A1 (https=)
CN (1) CN116096747A (https=)
WO (1) WO2021256524A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3244280A1 (en) 2022-02-17 2023-08-24 Rules-Based Medicine Inc. SINGLE-DOMAIN ANTIBODY BANK WITH MAXIMIZED ANTIBODY DEVELOPMENT CHARACTERISTICS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506720A (ja) * 2013-01-21 2016-03-07 アッヴィ・インコーポレイテッド 炎症性疾患のための抗ｔｎｆ及び抗ｉｌ１７併用治療薬バイオマーカー
JP2017518082A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7224585B2 (ja) 2018-12-27 2023-02-20 山田化学工業株式会社 フォトクロミック化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506720A (ja) * 2013-01-21 2016-03-07 アッヴィ・インコーポレイテッド 炎症性疾患のための抗ｔｎｆ及び抗ｉｌ１７併用治療薬バイオマーカー
JP2017518082A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AOKI, K. ET AL.: "Investigation of the immunogenicity of mirror-image single-domain antibody", 第57回ペプチド討論会講演要旨集, JPN6021034033, 27 October 2020 (2020-10-27), pages 15, ISSN: 0005656512 *
LI, J. ET AL.: "Total chemical synthesis of human interferon alpha-2b via native chemical ligation", J OF PEPT SCI, vol. 21, JPN6021034034, 2015, pages 554 - 560, ISSN: 0005764854 *
PENTELUTE, B.L. ET AL.: "Mirror Image Forms of Snow Flea Antifreeze Protein Prepared by Total Chemical Synthesis Have Identic", J AM CHEM SOC, vol. 130, JPN6021034035, 2008, pages 9702 - 9707, ISSN: 0005764855 *
REICHART, T. ET AL: "Development of Mirror-Image Monobodies for Targeted Cancer Therapies", J OF PEPTIDE SCIENCE, vol. Vol.24, Supplement 2, JPN6021034026, 2018, pages 67 - 68, ISSN: 0005764851 *
SHA, F. ET AL: "Monobodies and other synthetic binding proteins for expanding protein science", PROTEIN SCIENCE, vol. 26, JPN6021034029, 2017, pages 910 - 924, ISSN: 0005764853 *
大石 真也: "研究課題名：鏡像体タンパク質を用いた医薬品探索技術の開発と実証", 科学研究費助成事業データベース［ONLINE］, vol. 2018年度研究成果報告, JPN6021034028, 30 March 2020 (2020-03-30), ISSN: 0005764852 *

Also Published As

Publication number Publication date
CN116096747A (zh) 2023-05-09
WO2021256524A1 (ja) 2021-12-23
EP4169940A1 (en) 2023-04-26
US20230227536A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
JPWO2021256524A1 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106